Repligen (NASDAQ:RGEN) versus ADMA Biologics (NASDAQ:ADMA) Head to Head Analysis

Share on StockTwits

Repligen (NASDAQ:RGEN) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Earnings and Valuation

This table compares Repligen and ADMA Biologics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Repligen $194.03 million 18.06 $16.62 million $0.73 101.67
ADMA Biologics $16.99 million 12.78 -$65.74 million ($1.45) -2.60

Repligen has higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Repligen has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, ADMA Biologics has a beta of 2.93, indicating that its stock price is 193% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Repligen and ADMA Biologics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repligen 0 2 5 0 2.71
ADMA Biologics 0 0 7 0 3.00

Repligen currently has a consensus target price of $60.25, indicating a potential downside of 18.82%. ADMA Biologics has a consensus target price of $11.50, indicating a potential upside of 205.04%. Given ADMA Biologics’ stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Repligen.

Insider & Institutional Ownership

85.2% of Repligen shares are owned by institutional investors. Comparatively, 39.0% of ADMA Biologics shares are owned by institutional investors. 1.7% of Repligen shares are owned by company insiders. Comparatively, 16.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Repligen and ADMA Biologics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repligen 10.11% 6.35% 5.05%
ADMA Biologics -370.27% -210.69% -63.98%

Summary

Repligen beats ADMA Biologics on 9 of the 14 factors compared between the two stocks.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies, recombinant proteins, and vaccines; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell alternating tangential flow systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius tangential flow filters line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH and Sartorius Stedim Biotech to develop multiple affinity ligands. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Amcor plc  Given $10.74 Average Target Price by Brokerages
Amcor plc Given $10.74 Average Target Price by Brokerages
Zacks: EP Energy Corporation  Given $1.21 Consensus Target Price by Analysts
Zacks: EP Energy Corporation Given $1.21 Consensus Target Price by Analysts
Brokerages Expect Stoke Therapeutics  to Post  Earnings Per Share
Brokerages Expect Stoke Therapeutics to Post Earnings Per Share
Zacks: Analysts Expect CNH Industrial NV  to Post $0.29 Earnings Per Share
Zacks: Analysts Expect CNH Industrial NV to Post $0.29 Earnings Per Share
Exelixis, Inc.  Expected to Announce Earnings of $0.25 Per Share
Exelixis, Inc. Expected to Announce Earnings of $0.25 Per Share
Zacks: Analysts Anticipate Triplepoint Venture Growth BDC Corp  to Announce $0.38 Earnings Per Share
Zacks: Analysts Anticipate Triplepoint Venture Growth BDC Corp to Announce $0.38 Earnings Per Share


© 2006-2019 Ticker Report